USRE43898E1 - Altered antibodies and their preparation - Google Patents

Altered antibodies and their preparation Download PDF

Info

Publication number
USRE43898E1
USRE43898E1 US11/493,016 US49301691A USRE43898E US RE43898 E1 USRE43898 E1 US RE43898E1 US 49301691 A US49301691 A US 49301691A US RE43898 E USRE43898 E US RE43898E
Authority
US
United States
Prior art keywords
antibody
framework
seq
human
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/493,016
Other languages
English (en)
Inventor
Scott David Gorman
Michael Ronald Clark
Stephen Paul Cobbold
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE43898(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Priority to US11/493,016 priority Critical patent/USRE43898E1/en
Application granted granted Critical
Publication of USRE43898E1 publication Critical patent/USRE43898E1/en
Assigned to BTG INTERNATIONAL LIMITED reassignment BTG INTERNATIONAL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRITISH TECHNOLOGY GROUP INTERCORPORATE LICENSING LIMITED
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to altered antibodies and their preparation.
  • the invention is typically applicable to the production of humanised antibodies.
  • Antibodies typically comprise two heavy chains linked together by disulphide bonds and two light chains. Each light chain is linked to a respective heavy chain by disulphide bonds. Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end. The light chain variable domain is aligned with the variable domain of the heavy chain. The light chain constant domain is aligned with the first constant domain of the heavy chain. The constant domains in the light and heavy chains are not involved directly in binding the antibody to antigen.
  • variable domains of each pair of light and heavy chains form the antigen binding site.
  • the domains on the light and heavy chains have the same general structure and each domain comprises a framework of four regions, whose sequences are relatively conserved, connected by three complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • the four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of the antigen binding site.
  • the preparation of an altered antibody in which the CDRs are derived from a different species than the framework of the antibody's variable domains is disclosed in EP-A-0239400.
  • the CDRs may be derived from a rat or mouse monoclonal antibody.
  • the framework of the variable domains, and the constant domains, of the altered antibody may be derived from a human antibody.
  • Such a humanised antibody elicits a negligible immune response when administered to a human compared to the immune response mounted by a human against a rat or mouse antibody.
  • Humanised CAMPATH-1 antibody is disclosed in EP-A- 0328404.
  • the present invention provides a process for the preparation of an antibody chain in which the CDRs of the variable domain of the antibody chain are derived from a first mammalian species and the framework of the variable domain and, if present, the or each constant domain of the antibody chain are derived from a second different mammalian species, which process comprises:
  • variable domain of either or both chains of an antibody can therefore be altered by:
  • the antibody chain may be co-expressed with a complementary antibody chain. At least the framework of the variable domain and the or each constant domain of the complementary chain generally are derived from the said second species also. A light chain and a heavy chain may be co-expressed. Either or both chains may have been prepared by the process of the invention. Preferably the CDRs of both chains are.derived from the same selected antibody. An antibody comprising both expressed chains can be recovered.
  • the antibody preferably has the structure of a natural antibody or a fragment thereof.
  • the antibody may therefore comprise a complete antibody, a (Fab′) 2 fragment, a Fab fragment, a light chain dimer or a heavy chain.
  • the antibody may be an IgG such as an IgG1, IgG2, IgG3 or IgG4 IgM, IgA, IgE or IgD.
  • the antibody may be a chimaeric antibody of the type described in WO 86/01533.
  • a chimaeric antibody according to WO 86/01533 comprises an antigen binding region and a non-immunoglobulin region.
  • the antigen binding region is an antibody light chain variable domain or heavy chain variable domain.
  • the chimaeric antibody comprises both light and heavy chain variable domains.
  • the non-immunoglobulin region is fused at its C-terminus to the antigen binding region.
  • the non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme region, a region derived from a protein having known binding specificity, from a protein toxin or indeed from any protein expressed by a gene.
  • the two regions of the chimaeric antibody may be connected via as a cleavable linker sequence.
  • the invention is preferably employed to humanise an antibody, typically a monoclonal antibody and, for example, a rat or mouse antibody.
  • the framework and constant domains of the resulting antibody are therefore human framework and constant domains whilst the CDRs of the light and/or heavy chain of the antibody are rat or mouse CDRs.
  • Preferably all CDRs are rat or mouse CDRs.
  • the antibody may be a human IgG such as IgG1, IgG2, IgG3, IgG4; IgM; IgA; IgE or IgD carrying rat or mouse CDRs.
  • the process of the invention is carried out in such a way that the resulting antibody retains the antigen binding capability of the antibody from which it is derived.
  • An antibody is reshaped according to the invention by mutating the framework-encoding regions of DNA coding for the variable domains of the antibody. This antibody and the reshaped antibody should both be capable of binding to the same antigen.
  • variable domain framework of the antibody is preferably reshaped to about the closest variable domain framework of an antibody of another species.
  • about the closest is meant about the most homologous in terms of amino acid sequences.
  • Step 1 Determining the Nucleotide and Predicted Amino Acid Sequence of the Antibody Light and Heavy Chain Variable Domains
  • an antibody To reshape an antibody only the amino acid sequence of antibody's heavy and light chain variable domains needs to be known. The sequence of the constant domains is irrelevant because these do not contribute to the reshaping strategy.
  • the simplest method of determining an antibody's variable domain amino acid sequence is from cloned cDNA encoding the heavy and light chain variable domain.
  • Step 2 Designing the Reshaped Antibody
  • variable domain framework residues have little or no direct contribution.
  • the primary function of the framework regions is to hold the CDRs in their proper spacial orientation to recognize antigen.
  • substitution of rodent CDRs into a human variable domain framework is most likely to result in retention of their correct spacial orientation if the human variable domain is highly homologous to the rodent variable domain from which they originated.
  • a human variable domain should preferably be chosen therefore that is highly homologous to the rodent variable domain(s).
  • a suitable human antibody variable domain sequence can be selected as follows:
  • a cDNA encoding the desired reshaped antibody is preferably made beginning with the rodent cDNA from which the rodent antibody variable domain sequence(s) was originally determined.
  • the rodent variable domain amino acid sequence is compared to that of the chosen human antibody variable domain sequence.
  • the residues in the rodent variable domain framework are marked that need to be changed to the corresponding residue in the human to make the rodent framework identical to that of the human framework. There may also be residues that need adding to or deleting from the rodent framework sequence to make it identical to that of the human.
  • Oligonucleotides are synthesised that can be used to mutagenize the rodent variable domain framework to contain the desired residues. Those oligonucleotides can be of any convenient size. One is normally only limited in length by the capabilities of the particular synthesizer one has available. The method of oligonucleotide-directed in vitro mutagenesis is well known.
  • this method of reshaping as opposed to splicing CDRs into a human framework are that (1) this method does not require a pre-existing cDNA encoding the human framework to which to reshape and (2) splicing CDRs is technically more difficult because there is usually a large region of poor homology between the mutagenic oligonucleotide and the human antibody variable domain. This is not so much a problem with the method of splicing human framework residues onto a rodent variable domain because there is no need for a pre-existing cDNA encoding the human variable domain. The method starts instead with the rodent cDNA sequence.
  • splicing framework regions is technically easier because there is a high degree of homology between the mutagenic oligonucleotide and the rodent variable domain framework. This is true because a human antibody variable domain framework has been selected that is most homologous to that of the rodent.
  • the advantage of the present method of reshaping as opposed to synthesizing the entire reshaped version from scratch is that it is technically easier. Synthesizing a reshaped variable domain from scratch requires several more oligonucleotides, several days more work, and technical difficulties are more likely to arise.
  • Step 4 The Transfection and Expression of the Reshaped Antibody
  • a reshaped antibody may therefore be prepared by a process comprising:
  • the DNA sequence in step a) encodes both the variable domain and the or each constant domain of the antibody chain, the or each constant domain being derived from the first antibody.
  • the antibody can be recovered and purified.
  • the cell line which is transformed to produce the altered antibody may be a Chinese Hamster Ovary (CHO) cell line or an immortalised mammalian cell line, which is advantageously of lymphoid origin, such as a myeloma, hybridoma, trioma or quadroma cell line.
  • the cell line may also comprise a normal lymphoid cell, such as a B-cell, which has been immortalised by transformation with a virus, such as the Epstein-Barr virus.
  • the immortalised cell line is a myeloma cell line or a derivative thereof.
  • the cell line used to produce the altered antibody is preferably a mammalian cell line
  • any other suitable cell line such as a bacterial cell line or a yeast cell line
  • E. coli—derived bacterial strains could be used.
  • step (b) may be carried out by further manipulating the vector produced in step (a) so that this vector encodes not only the variable domain of an altered antibody light or heavy chain, but also the complementary variable domain.
  • step (b) is carried out by preparing a second vector which is used to transform the immortalised cell line.
  • This alternative leads to easier construct preparation, but may be less preferred than the first alternative in that it may not lead to as efficient production of antibody.
  • the transformed cell line may be produced for example by transforming a suitable bacterial cell with the vector and then fusing the bacterial cell with the immortalised cell Line by spheroplast fusion.
  • the DNA may be directly introduced into the immortalised cell line by electroporation or other suitable method.
  • An antibody is consequently produced in which CDRs of a variable domain of an antibody chain are homologous with the corresponding CDRs of an antibody of a first mammalian species and in which the framework of the variable domain and the constant domains of the antibody are homologous with the corresponding framework and constant domains of an antibody of a second, different, mammalian species.
  • all three CDRs of the variable domain of a light or heavy chain are derived from the first species.
  • the present process has been applied to obtain an antibody against human CD4 antigen. Accordingly, the invention also provides an antibody which is capable of binding to human CD4 antigen, in which the CDRs of the light chain of the antibody have the amino acid sequences:
  • CDR1 NYGMA (SEQ ID NO:16)
  • CDR2 TISHDGSDTYFRDSVKG (SEQ ID NO:17)
  • the framework of the variable domain and, if present, the or each constant domain of each chain are derived from a mammalian non-rat species.
  • the antibody preferably has the structure of a natural antibody or a fragment thereof.
  • the antibody may therefore comprise a complete antibody, a (Fab′) 2 fragment, a Fab fragment, a light chain dimer or a heavy chain.
  • the antibody may be an IgG such as IgG1, IgG2, IgG3 or IgG4 IgM, IgA, IgE or IgD.
  • the antibody may be a chimaeric antibody of the type described in WO 86/01533.
  • a chimaeric antibody according to WO 86/01533 comprises an antigen binding region and a non-immunoglobulin region.
  • the antigen binding region is an antibody light chain variable domain or heavy chain variable domain.
  • the chimaeric antibody comprises both light and heavy chain variable domains.
  • the non-immunoglobulin region is fused at its C-terminus to the antigen binding region.
  • the non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme region, a region derived from a protein having known binding specificity, from a protein toxin or indeed from any protein expressed by a gene.
  • the two regions of the chimaeric antibody may be connected via a cleavable linker sequence.
  • the invention is preferably employed to humanise a CD4 antibody such as a rat or mouse CD4 antibody.
  • the framework and the constant domains of the resulting antibody are therefore human framework and constant domains whilst the CDRs of the light and/or heavy chain of the antibody are rat or mouse CDRs.
  • Preferably all CDRs are rat or mouse CDRs.
  • the antibody may be a human IgG such as IgG1, IgG2, IgG3, IgG4; IgM; IgA; IgE or IgD carrying rat or mouse CDRs.
  • the framework of the antibody heavy chain is homologous to the corresponding framework of the human antibody KOL (Schmidt et al, Hoppe-Seyler's Z. Physiol. Chem., 364 713-747, 1983).
  • the sixth residue of framework 4 in this case is suitably Thr or Pro, preferably Thr.
  • This residue is the 121st residue in the KOL antibody heavy chain variable region (Schmidt et al, 1983), and is identified as residue 108 by Kabat (Kabat et al, “Sequences of proteins of immunological interest”, US Dept of Health and Human Services, US Government Printing Office, 1987).
  • the framework of the antibody heavy chain is homologous to the corresponding framework of the human antibody NEW (Saul et al, J. Biol. Chem. 2: 585-597, 1978).
  • the final residue of framework 1 in this case is suitably Ser or Thr, preferably Ser. This residue is at position 30 (Kabat et al, 1987).
  • the framework of the antibody light chain is homologous to the variable domain framework of the protein REI (Epp et al, Eur. J. Biochem., 45, 513-524, 1974).
  • the framework regions of one or both chains of a CD4 antibody can be reshaped by the present process.
  • one or both chains of a CD4 antibody may be reshaped by the procedure described in EP-A-0239400.
  • the procedure of EP-A-0239400 involves replacing CDRs rather than the replacement of frameworks.
  • the CDRs are grafted onto a framework derived from a mammalian non-rat species, typically a human. This may be achieved by oligonucleotide-directed in vitro mutagenesis of the CDR-encoding regions of an antibody chain, light or heavy, from a mammalian non-rat species.
  • the oligonucleotides in such an instance are selected so that the resulting CDR-grafted antibody has the light chain CDRs 1 to 3 and the heavy chain CDRs 1 to 3 shown above.
  • the reshaped CD4 antibody can be used to induce tolerance to an antigen. It can be used to alleviate autoimmune diseases such as rheumatoid arthritis. It can be used to prevent graft rejection. Tolerance to a graft such as an organ graft or a bone marrow transplantation can be achieved. Also, the reshaped CD4 antibody might be used to alleviate allergies. Tolerance to allergens could be achieved.
  • the CD4 antibody may be depleting or non-depleting.
  • a depleting antibody is an antibody which depletes more than 50%, for example from 90 to 99%, of target cells in vivo.
  • a non-depleting antibody depletes fewer than 50%, for example, from 10 to 25% and preferably less than 10% of target cells in vivo.
  • a CD4 antibody may be administered alone or may be co-administered with a non-depleting or depleting CD8 antibody.
  • the CD4 antibody, depleting or non-depleting, and CD8 monoclonal antibody, depleting or non-depleting may be administered sequentially in any order or may be administered simultaneously.
  • An additional antibody, drug or protein may be administered before, during or after administration of the antibodies.
  • a CD4 antibody and, indeed, a CD8 antibody as appropriate are given parenterally, for example intravenously.
  • the antibody may be administered by injection or by infusion.
  • the antibody is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or diluent. Any appropriate carrier or diluent may be employed, for example phosphate-buffered saline solution.
  • the amount of non-depleting or depleting CD4 and, if desired, CD8 antibody administered to a patient depends upon a variety of factors including the age and weight of a patient, the condition which is being treated and the antigen (s) to which it is desired to induce tolerance.
  • a mAb In a model mouse system from 1 ⁇ g to 2 mg, preferably from 400 ⁇ g to 1 mg, of a mAb is administered at any one time.
  • 3 to 500 mg, for example from 5 to 200 mg, of antibody may be administered at any one time. Many such doses may be given over a period of several weeks, typically 3 weeks.
  • a foreign antigen(s) to which it is desired to induce tolerance can be administered to a host before, during, or after a course of CD4 antibody (depleting or non-depleting) and/or CDs antibody (depleting or non-depleting). Typically, however, the antigen(s) is administered one week after commencement of antibody administration, and is terminated three weeks before the last antibody administration.
  • Tolerance can therefore be induced to an antigen in a host by administering non-depleting or depleting CD4 and CD8 mAbs and, under cover of the mAbs, the antigen.
  • a patient may be operated on surgically under cover of the non-depleting or depleting CD4 and CD8 mAbs to be given a tissue transplant such as an organ graft or a bone marrow transplant.
  • tolerance may be induced to an antigen already possessed by a subject. Long term specific tolerance can be induced to a self antigen or antigens in order to treat autoimmune disease such as multiple sclerosis or rheumatoid arthritis. The condition of a patient suffering from autoimmune disease can therefore be alleviated.
  • FIGS. 1-1A shows the nucleotide and predicted amino acid sequence of rat CD4 antibody light chain variable region. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively.
  • Base pairs 1-269 HindIII-PvuII
  • 577-620 [Bg 1 II/Bc 1 I]-BamHI) are part of the vector M13V K PCR3, while base pairs 270-576 are from the PCR product of the CD4 antibody light chain variable region (V L ).
  • CDRs (boxes) were identified by comparison to known immunological sequences (Kabat et al, “Sequences of proteins of immunological interest, US Dept of Health and Human Services, US Government Printing Office, 1987).
  • the nucleotide sequence of FIG. 1 corresponds to SEQ ID NO:1.
  • FIGS. 2-2A shows the nucleotide and predicted amino acid sequence of the reshaped CAMPATH-1 antibody light chain cDNA. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. The nucleotide sequence of FIG. 2 corresponds to SEQ ID NO:2.
  • FIGS. 3-3A shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody light chain cDNA CD4V L REI. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. The nucleotide sequence of FIG. 3 corresponds to SEQ ID NO:3.
  • FIGS. 4-4A shows the nucleotide and predicted amino acid sequence of rat CD4 antibody heavy chain variable region. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. Base pairs 1-272 (HindIII-PstI) and 603-817 (BstEII-BamHI) are part of the vector M13V H PCR1, while base pairs 273-602 are from the PCR product of the CD4 antibody heavy chain variable region (V H ).
  • the nucleotide sequence of FIG. 4 corresponds to SEQ ID NO:4.
  • FIGS. 5 , 5 A-D shows the nucleotide and predicted amino acid sequence of the reshaped CAMPATH-1 antibody heavy chain cDNA. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. The nucleotide sequence of FIG. 5 corresponds to SEQ ID NO:5.
  • FIGS. 6 , 6 A-D shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain cDNA CD4V H NEW-Thr 30 .
  • the number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively.
  • CDRs are identified by boxes.
  • the nucleotide sequence of FIG. 6 corresponds to SEQ ID NO:6.
  • FIGS. 7 , 7 A-D shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain cDNA CD4V H NEW-Ser 30 .
  • the number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively.
  • CDRs are identified by boxes.
  • the nucleotide sequence of FIG. 7 corresponds to SEQ ID NO:7.
  • FIG. 8 shows the heavy chain variable (V) region amino acid sequence of the human myeloma protein KOL. CDRs are identified by boxes. This sequence is taken from the Swiss-Prot protein sequence database. The nucleotide sequence of FIG. 8 corresponds to SEQ ID NO:8.
  • FIGS. 9-9A shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain V region CD4V H KOL-Pro 113 .
  • the number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes.
  • the nucleotide sequence of FIG. 9 corresponds to SEQ ID NO:9.
  • FIGS. 10-10A shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain V region CD4V H KOL-Pro 113 without immunoglobulin promoter. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. The nucleotide sequence of FIG. 10 corresponds to SEQ ID NO:10.
  • FIGS. 11-11A shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain V region CD4V H KOL-Thr 113 .
  • the number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively.
  • CDRs are identified by boxes.
  • the nucleotide sequence of FIG. 11 corresponds to SEQ ID NO:11.
  • FIGS. 12-12A shows the nucleotide and predicted amino acid sequence of the reshaped CD4 antibody heavy chain V region CD4V H KOL-Thr 113 without immunoglobulin promoter. The number of the first and last amino acid or nucleotide in each line is indicated in the left and right margins, respectively. CDRs are identified by boxes. The nucleotide sequence of FIG. 12 corresponds to SEQ ID NO:12.
  • FIG. 13 shows the results of an ELISA that compares the avidity of YNB46.1.8 and CD4V H KOL-Thr 113 antibodies.
  • the X-axis indicates the concentration ( ⁇ g/ml) of YNB46.1.8 (triangles) or CD4V H KOL-Thr 113 (circles) antibody.
  • the Y-axis indicates the optical density at 492 nanometers.
  • the rat-derived anti-human CD4 antibody, clone YNB46.1.8 (IgG 2b , kappa light chain serotype), was the result of fusion between a rat splenocyte and the Lou strain rat myeloma cell line Y3-Ag 1.2.3 (Galfre et al, Nature, 277: 131-133, 1979) and was selected by its binding to a rat T cell line NB2-6TG stably transfected with an expression vector containing a complementary DNA (cDNA) encoding the human CD4 antigen (Madden et al, Cell, 42: 93-104, 1985). Antibody was purified by high pressure liquid chromatography (HPLC).
  • HPLC high pressure liquid chromatography
  • a 25 ⁇ l first strand synthesis reaction consisted of 5 ⁇ g poly(A) + RNA, 250 ⁇ M each dNTP, 50 mM Tris.HCl (pH 8.2 at 42° C.), 10 mM MgCl 2 , 100 mM KCl, 10 mM dithiothreitol, 23 units reverse transcriptase (Anglian Biotec, Colchester, U.K.), 3.5 pmoles of the V L region-specific oligonucleotide primer V K 1FOR [5′-d(GTT AGA TCT CCA GCT TGG TCC C)SEQ ID NO:19] or the V H region-specific prime V H 1FOR-B [5,-d(TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC)SEQ ID NO:20], and incubated for 5 minutes at 20° C. and then 90 minutes at 42° C.
  • the samples were frozen at ⁇ 20° C. and the mineral oil (a viscous liquid at ⁇ 20° C.) was removed by aspiration.
  • the aqueous phases were thawed, and PCR products were purified by electrophoresis in 2% agarose gels, and then double digested with either PvuII and Bg 1 II (V L ) or PstI and BstEII (V H ) restriction enzymes, and cloned into the PvuII and Be 1 I restriction sites of the vector M13V K PCR3 (for V L region; Orlandi et al, 1989) or the PstI and BstEII restriction sites of the vector M13V H PCR1 (for V H region).
  • V L region clones were first screened by hybridisation to a 32 P-labeled oligonucleotide probe [5′-d(GTT TCA TAA TAT TGG AGA CA)SEQ ID NO:23] for the CDR2 of the Y3-Ag 1.2.3 V L region.
  • V L region clones not hybridising to this probe and V H region clones were sequenced by the dideoxy chain termination method (Sanger et al, PNAS USA 74: 5463, 1977).
  • the reshaped light chain was constructed by oligonucleotide-directed in vitro mutagenesis in an M13 vector by priming with three oligonucleotides simultaneously on a 748 base single-stranded cDNA template encoding the entire V L and kappa constant (C K ) regions of the reshaped CAMPATH-1 antibody (Reichmann et al, Nature 332: 323-327, 1988).
  • the three oligonucleotides [5′-d(AGA GTG ACC ATC ACC TGT CTA GCA AGT GAG GAC ATT TAC AGT GAT TTA GCA TGG TAC CAG CAG AAG CCA)SEQ ID NO:24, 5′-d(CTG CTG ATC TAC AAT ACA GAT ACC TTG CAA AAT GGT GTG CCA AGC AGA TTC)SEQ ID NO:25, 5′-d(ATC GCC ACC TAC TAC TGC CAA CAG TAT AAC AAT TAT CCG TGG ACG TTC GGC CAA GGG ACC)SEQ ID NO:26] were designed to replace each of the three CDRs in the REI-based human antibody V L region framework that is part of the reshaped CAMPATH-1 antibody V L region (Reichmann et al, 1988).
  • a clone containing each of the three mutant oligonucleotides was identified by nucleotide sequencing and was subcloned into the HindIII site of the expression vector pH ⁇ APr-1 (Gunning et al, PNAS, 4: 4831-4835, 1987) which also contained a dihydrofolate reductase gene (Ringold et al, J. Mol. Appl. Genet. 1: 165-175, 1981) driven by a truncated SV40 promoter.
  • CD4V H NEW-Thr 30 Two versions of the NEW-based reshaped heavy chain were created, CD4V H NEW-Thr 30 and CD4V H NEW-Ser 30 .
  • the CD4V H NEW-Thr 30 version ( FIG. 6 ) encodes a threonine residue at position 30 while the CD4V H NEW-Ser 30 version ( FIG. 7 ) encodes a Ser residue at position 30.
  • CD4V H NEW-Thr 30 was created first by oligonucleotide-directed in vitro mutagenesis in the vector M13mp18 by priming with three oligonucleotides simultaneously on a 1467 base single-stranded cDNA template ( FIG.
  • the three oligonucleotides [5′-d(TCT GGC TTC ACC TTC ACC AAC TAT GGC ATG GCC TGG GTG AGA CAG CCA CCT) SEQ ID NO:27, 5′-d(GGT CTT GAG TGG ATT GGA ACC ATT AGT CAT GAT GGT AGT GAC ACT TAC TTT CGA GAC TCT GTG AAG GGG AGA GTG)SEQ ID NO:28, 5′-d(GTC TAT TAT TGT GCA AGA CAA GGC ACT ATA GCT GGT ATA CGT CAC TGG GGT CAA GGC AGC CTC)SEQ ID NO:29] were designed to replace each of the three complementarity determining regions (CDRs) in the NEW-based V H region that is part of the reshaped CAMPATH-1 antibody (Reichmann et al, 1988).
  • the three oligonucleotides [5′-d(TCT GGC TTC ACC T
  • CD4V H NEW-Ser 30 was created second by oligonucleotide-directed in vitro mutagenesis in the vector M13mp18 by priming with a single oligonucleotide on the 1458 base single-stranded cDNA template ( FIG. 6 ) encoding CD4V H NEW-Thr 30 .
  • Th oligonucleotide [5′-d(GCT TCA CCT TCA GCA ACT ATG GCA T)SEQ ID NO:30] was designed to mutate the residue at position 30 from threonine [ACC] to serine [AGC].
  • a clone ( FIG. 7 ) containing this mutant oligonucleotide was identified by nucleotide sequencing. Double-stranded forms of the clones CD4V H NEW-Thr 30 and CD4V H NEW-Ser 30 were sub-cloned as HindIII fragments into the HindIII site of the expression vector pNH316.
  • the vector pNH316 is a modified version of the vector pH ⁇ APr-1 (Gunning et al, PNAS, 84: 4831-4835, 1987) which was engineered to contain a neomycin resistance gene driven by a metallothionine promoter.
  • CD4V H KOL-Thr 113 Two versions of the KOL-based reshaped heavy chain were created, CD4V H KOL-Thr 113 and CD4V H KOL-Pro 113 .
  • the CD4V H KOL-Thr 113 version encodes a threonine residue at position 113 ( FIG. 11 ) while the CD4V H KOL-Pro 113 version encodes a proline residue at position 113 ( FIG. 9 ).
  • CD4V H KOL-Thr 113 was created first by oligonucleotide-directed in vitro mutagenesis of single-stranded DNA template containing the 817 base HindIII-BamHI fragment encoding the V H region of the rat CD4 antibody ( FIG.
  • CD4V H KOL-Pro 113 was created second by oligonucleotide-directed in vitro mutagenesis of single-stranded DNA template containing the 817 base HindIII-BamHI fragment encoding CD4V H KOL-Thr 113 cloned into M13mp18 by priming with the oligonucleotide [5′-d(TGG GGC CAA GGG ACC CCC GTC ACC GTC TCC TCA)SEQ ID NO:36].
  • a clone containing this mutant oligonucleotide was identified by nucleotide sequencing.
  • the immunoglobulin promoters were removed from the double-stranded DNA forms of clones encoding CD4V H KOL-Thr 113 ( FIG. 11 ) and CD4V H KOL-Pro 113 ( FIG. 9 ) by replacing (for both versions) the first 125 bp (HindIII-NcoI) with a HindIII-NcoI oligonucleotide linker fragment [5′-d(AGC TTT ACA GTT ACT GAG CAC ACA GGA CCT CAC)SEQ ID NO:37 and its overlapping complement 5′-d(CAT GGT GAG GTC CTG TGT GCT CAG TAA CTG TAA)SEQ ID NO:38].
  • the relative affinities of the reshaped antibodies to bind the CD4 antigen were estimated by FACS analysis.
  • the CD4-expressing cells used in this analysis were a cloned rat T cell line NB2-6TG stabily transfected with an expression vector containing a complementary DNA (cDNA) encoding the human CD4 antigen (Maddon et al, Cell, 42, 93-104, 1985). Cells were stained with the appropriate reshaped antibody followed by fluorescein-conjugated sheep anti-human antibodies (Binding Site Ltd., Birmingham, UK). Control staining (see Table 1) consisted of no antibody present during the first stage of cell staining. Mean cellular fluorescence was determined with an Ortho FACS.
  • the relative avidities of the rat YNB46.1.8 antibody and the reshaped CD4V H KOL-Thr 113 antibody were estimated by an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • Microtiter plates were coated with soluble recombinant CD4 antigen (Byrn et al, Nature, 344: 667-670, 1990) at 50 ul/well, 10 ug/ml, and then blocked with 100 ul/well phosphate buffered saline (PBS) containing 1.0% bovine serum albumin (BSA).
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • Antibodies were diluted in PBS containing 0.1% BSA, and added to wells (50 ul/well) for 45 minutes at room temperature.
  • Biotinylated CD4V H KOL-Thr 113 antibody (10 ul/well; 20 ug/ml final concentration) was then added to each well for an additional 45 minutes. Wells were washed with PBS containing 0.1% BSA, and then 50 ul streptavidin-biotinylated horseradish peroxidase complex (Amersham; Aylesbury, UK) diluted 1:1,000 was added to each well for 30 minutes. Wells were washed with PBS containing 0.1% BSA, and 100 ul substrate (25 mM citric acid, 50 mM disodium hydrogen phosphate, 0.1% (w/v) o-phenylene diamine, 0.04% (v/v) 30% hydrogen peroxide) was added to each well. Reactions were stopped by the addition of 50 ul/well 1.0 M sulfuric acid. Optical densities at 492 nanometers (OD 492 ) were determined with an ELISA plate reader.
  • Dihydrofolate reductase deficient chinese hamster ovary (CHO DHFR- ) cells 10 6 /T-75 flask were cotransfected as described (Wigler et al, PNAS USA 76, 1373, 1979) with 9 ⁇ g of heavy chain construct and 1 ⁇ g of the light chain construct. Transfectants were selected in medium containing 5% dialysed foetal bovine serum for 2 to 3 weeks, and antibody-secreting clones were identified by ELISAs of conditioned media. Antibody was concentrated and purified by protein-A Sepharose (Trade Mark) column chromatography.
  • V L and V H regions from CD4 antibody-secreting hybridoma cells were isolated by PCR using primers which amplify the segment of mRNA encoding the N-terminal region through to the J region (Orlandi et al, 1989).
  • V L and V H region PCR products were subcloned into the M13-based vectors M13V K PCR3 and M13V H PCR1, respectively.
  • FIGS. 1 and 4 The cDNA sequences and their predicted amino acid sequences are shown in FIGS. 1 and 4 . As no additional V L or V H region-encoding clones were found, it was assumed that these sequences were derived from the CD4 antibody genes.
  • CD4V H NEW-Thr 30 ( FIG. 6 ) encoding a threonine residue at position 30 (in framework 1)
  • CD4V H NEW-Ser 30 ( FIG. 7 ) encoding a serine residue at position 30.
  • the CD4 antibody V H region in the second reshaping strategy, we have reshaped the CD4 antibody V H region to contain the V H region framework sequences of the human antibody KOL.
  • the overall amino acid sequence of the V H region of KOL is most homologous to the rat CD4 antibody V H region.
  • the V H regions of the human antibodies KOL and NEW are 66% and 42% homologous to the rat CD4 antibody V H region, respectively.
  • CD4V H KOL-Pro 113 ( FIG. 10 ) encodes a proline residue at position 113 and CD4V H KOL-Thr 113 ( FIG. 12 ) encodes a threonine residue at position 113.
  • CD4V H KOL-Pro 113 is “true to form” in that its framework sequences are identical to those of the KOL antibody heavy chain V region ( FIG. 8 ).
  • the overall amino acid sequence of the V L region of the human light chain NEW is most homologous (67%) to the rat CD4 antibody V L region.
  • CD4V L REI identical reshaped light chain
  • CD4V H NEW-Thr 30 and CD4V H NEW-Ser 30 identical reshaped CD4 antibody heavy chains
  • CD4V H KOL-Pro 113 and CD4V H KOL-Thr 113 are also expressed with the KOL-based reshaped CD4 antibody heavy chains CD4V H KOL-Pro 113 and CD4V H KOL-Thr 113 .
  • the reshaped light chain of each antibody is called CD4V L REI.
  • the reshaped heavy chains of the antibodies are called CD4V H NEW-Thr 30 , CD4V H NEW-Ser 30 , CD4V H KOL-Pro 113 , and CD4V H KOL-Thr 113 , respectively.
  • Each of the reshaped heavy chains contain the same human IgG1 constant region.
  • the name of a reshaped antibody's heavy chain shall be used below to refer to the whole antibody (heavy and light chain combination).
  • the relative affinities of the reshaped antibodies were approximated by measuring their ability to bind to CD4 antigen-expressing cells at various antibody concentrations. FACS analysis determined the mean cellular fluorescence of the stained cells (Table 1).
  • CD4V H KOL-Thr 113 antibody binds CD4 + cells when compared to the control, reshaped CAMPATH-1 antibody.
  • CD4V H KOL-Thr 113 antibody binds CD4 + cells with far greater affinity than CD4V H NEW-Thr 30 antibody.
  • the lowest concentration of CD4V H KOL-Thr 113 antibody tested (2.5 ug/ml) gave a mean cellular fluorescence nearly equivalent to that of the highest concentration of CD4V H NEW-Thr 30 antibody tested (168 ug/ml).
  • CD4V H NEW-Ser 30 antibody may bind CD4 + cells somewhat better than CD4V H NEW-Thr 30 . Only 2.5 ug/ml CD4V H NEW-Ser 30 antibody is required to give a mean cellular fluorescence nearly equivalent to 10 ug/ml CD4V H NEW-Thr 30 antibody.
  • CD4V H KOL-Thr 113 antibody may bind CD4 + cells somewhat better than CD4V H KOL-Pro 113 antibody.
  • each of the reshaped CD4 antibodies used in the above experiments have the identical heavy chain constant regions, and are associated with identical reshaped light chains. Thus observed differences of binding to CD4+ cells must be due to differences in their heavy chain V regions.
  • the relative avidities of the rat YNB46.1.8 antibody and the reshaped CD4V H KOL-Thr 113 antibody were estimated by ELISA. In this assay, the ability of each antibody to inhibit the binding of biotinylated CD4V H KOL-Thr 113 antibody to soluble recombinant CD4 antigen was determined. Results of an experiment are shown in FIG. 13 .
  • the inhibition of binding of biotinylated CD4V H KOL-Thr 113 antibody was linear for both the unlabeled CD4V H KOL-Thr 113 and YNB46.1.8 antibodies near the optical density of 0.3.
  • the concentrations of CD4V H KOL-Thr 113 and YNB46.1.8 antibodies that give an optical density of 0.3 are 28.7 and 1.56 ug/ml, respectively.
  • the avidity of the YNB46.1.8 antibody can be estimated to be 28.7/1.56 or about 18 times better than that of CD4V H KOL-Thr 113 antibody. It should be noted that this experiment only provides a rough approximation of relative avidities, not affinities.
  • the rat YNB46.1.8 antibody contains a different constant region than that of the CD4V H KOL-Thr 113 antibody, and this could affect how well the antibodies bind CD4 antigen, irrespective of their actual affinities for CD4 antigen.
  • the actual affinity of the reshaped antibodies for CD4 antigen may be greater, lesser, or the same as the YNB46.1.8 antibody.
  • the other reshaped antibodies CD4V H KOL-Pro 113 , CD4V H NEW-Ser 30 , and CD4V H NEW-Thr 30 have not yet been tested in this assay.
  • CD4V H KOL-Pro 113 100 594.9 CD4V H KOL-Pro 113 40 372.0 CD4V H KOL-Pro 113 10 137.7 CD4V H KOL-Pro 113 2.5 48.9 CD4V H KOL-Thr 113 100 696.7 CD4V H KOL-Thr 113 40 631.5 CD4V H KOL-Thr 113 10 304.1 CD4V H KOL-Thr 113 2.5 104.0 CONTROL — 12.3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/493,016 1990-09-17 1991-09-16 Altered antibodies and their preparation Expired - Lifetime USRE43898E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/493,016 USRE43898E1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909020282A GB9020282D0 (en) 1990-09-17 1990-09-17 Altered antibodies and their preparation
GB9020282 1990-09-17
US11/493,016 USRE43898E1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation
PCT/GB1991/001578 WO1992005274A1 (en) 1990-09-17 1991-09-16 Framework mutated antibodies and their preparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/030,175 Reissue US6767996B1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation

Publications (1)

Publication Number Publication Date
USRE43898E1 true USRE43898E1 (en) 2013-01-01

Family

ID=10682322

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/683,113 Expired - Lifetime USRE46877E1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation
US11/493,016 Expired - Lifetime USRE43898E1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation
US08/030,175 Ceased US6767996B1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation
US08/459,655 Expired - Lifetime US7098006B1 (en) 1990-09-17 1995-06-02 Chimeric antibody, pharmaceutical composition and process of its production
US11/114,233 Abandoned US20070212753A1 (en) 1990-09-17 2005-04-26 Altered antibodies and their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/683,113 Expired - Lifetime USRE46877E1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation

Family Applications After (3)

Application Number Title Priority Date Filing Date
US08/030,175 Ceased US6767996B1 (en) 1990-09-17 1991-09-16 Altered antibodies and their preparation
US08/459,655 Expired - Lifetime US7098006B1 (en) 1990-09-17 1995-06-02 Chimeric antibody, pharmaceutical composition and process of its production
US11/114,233 Abandoned US20070212753A1 (en) 1990-09-17 2005-04-26 Altered antibodies and their preparation

Country Status (20)

Country Link
US (5) USRE46877E1 (ja)
EP (1) EP0549581B2 (ja)
JP (1) JPH06502762A (ja)
KR (1) KR100217212B1 (ja)
AT (1) ATE148172T1 (ja)
AU (1) AU660151B2 (ja)
CA (1) CA2091769C (ja)
DE (1) DE69124387T3 (ja)
DK (1) DK0549581T3 (ja)
ES (1) ES2097808T3 (ja)
GB (1) GB9020282D0 (ja)
GR (1) GR3023252T3 (ja)
ID (1) ID1044B (ja)
IE (1) IE913257A1 (ja)
IL (1) IL99499A (ja)
MX (1) MX9101117A (ja)
MY (1) MY111682A (ja)
NZ (1) NZ239826A (ja)
WO (1) WO1992005274A1 (ja)
ZA (1) ZA917407B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46877E1 (en) * 1990-09-17 2018-05-29 Btg International Limited Altered antibodies and their preparation

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE69627665T2 (de) * 1995-05-18 2004-02-19 Ortho-Mcneil Pharmaceutical, Inc. Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CA2443437A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US8165535B2 (en) * 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
CA2574881C (en) * 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
JP2009504136A (ja) * 2005-05-24 2009-02-05 アベスタゲン リミテッド 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法
AU2008203703C1 (en) 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
US8519106B2 (en) 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20100239570A1 (en) 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2595376T3 (es) 2009-12-10 2016-12-29 Regeneron Pharmaceuticals, Inc. Ratones que producen anticuerpos de cadena pesada
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
DK2758433T3 (en) 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
JP6316195B2 (ja) 2011-10-26 2018-04-25 エランコ ティーアゲズンタイト アーゲー モノクローナル抗体および使用の方法
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
PL2797951T3 (pl) 2011-12-28 2018-07-31 Immunoqure Ag Sposób izolacji ludzkich przeciwciał
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0200412A2 (en) 1985-04-17 1986-11-05 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US4652447A (en) 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
EP0323806A1 (en) 1988-01-05 1989-07-12 Ciba-Geigy Ag Novel chimeric antibodies
EP0327000A2 (en) 1988-01-30 1989-08-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Gene fragments coding for the variable region of an anti-HIV antibody, chimeric anti-HIV antibodies expressed using the same, and process for their preparation
EP0328404A1 (en) 1988-02-12 1989-08-16 Btg International Limited Modified antibodies
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0365209A2 (en) 1988-10-17 1990-04-25 Becton, Dickinson and Company Anti-leu 3A amino acid sequence
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
EP0380018A2 (en) 1989-01-23 1990-08-01 Abbott Laboratories Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
EP0403156A1 (en) 1989-06-07 1990-12-19 Genzyme Corporation Improved monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
EP0409242A1 (en) 1989-07-21 1991-01-23 The Calpis Food Industry Co., Ltd. Monoclonal antibody against human CD4 peptide
WO1991007492A1 (en) 1989-11-13 1991-05-30 Central Blood Laboratories Authority Monoclonal antibodies
WO1991009966A1 (en) 1989-12-21 1991-07-11 Ortho Pharmaceutical Corporation Cd4 specific recombinant antibody
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545403A (en) 1990-10-17 1996-08-13 Burroughs Wellcome Co. Method for treating a mammal by administering a CHO-glycosylated antibody
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652447A (en) 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
EP0200412A2 (en) 1985-04-17 1986-11-05 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
EP0323806A1 (en) 1988-01-05 1989-07-12 Ciba-Geigy Ag Novel chimeric antibodies
EP0327000A2 (en) 1988-01-30 1989-08-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Gene fragments coding for the variable region of an anti-HIV antibody, chimeric anti-HIV antibodies expressed using the same, and process for their preparation
EP0328404A1 (en) 1988-02-12 1989-08-16 Btg International Limited Modified antibodies
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0365209A2 (en) 1988-10-17 1990-04-25 Becton, Dickinson and Company Anti-leu 3A amino acid sequence
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
EP0380018A2 (en) 1989-01-23 1990-08-01 Abbott Laboratories Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
EP0403156A1 (en) 1989-06-07 1990-12-19 Genzyme Corporation Improved monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
EP0409242A1 (en) 1989-07-21 1991-01-23 The Calpis Food Industry Co., Ltd. Monoclonal antibody against human CD4 peptide
WO1991007492A1 (en) 1989-11-13 1991-05-30 Central Blood Laboratories Authority Monoclonal antibodies
WO1991009966A1 (en) 1989-12-21 1991-07-11 Ortho Pharmaceutical Corporation Cd4 specific recombinant antibody
WO1991009967A1 (en) 1989-12-21 1991-07-11 Celltech Limited Humanised antibodies
US5545403A (en) 1990-10-17 1996-08-13 Burroughs Wellcome Co. Method for treating a mammal by administering a CHO-glycosylated antibody
EP0822255A2 (en) * 1990-10-17 1998-02-04 The Wellcome Foundation Limited CHO (Chinese Hamster Ovary) glycosylated antibodies and their use in therapy

Non-Patent Citations (75)

* Cited by examiner, † Cited by third party
Title
Amit et al. Science, 233:747-753, Aug. 15, 1986. *
Brüggemann M. et al., "Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies," J Exp Med., 166:1351-61 (1987).
Bruggemann, et al., J. Exp. Med., 1987, pp. 1351-1361.
Burgess W.H. et al., "Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue," J Cell Biol., 111:2129-38 (1990).
Burgess, et al., The Journal of Cell Biology, 111 (1990), pp. 2129-2138.
Byrn et al., Nature, 344, 1990, pp. 667-670.
Byrn R.A. et al., "Biological Properties of a CD4 Immunoadhesin," Nature, 344:667-70 (1990).
Carter P. et al., "Improved oligonucleotide Side-Directed Mutagenesis Using M13 Vectors," Nucleic Acids Res. 13(12):4431-43 (1985).
Carteron N. L. et al., "Treatment of Murine Lupus with F(ab')2 Fragments of Monoclonal Antibody to L3T4: suppression of autoimmunity does not depend on T helper cell depletion.," J Immunol., 142:1470-75 (1988).
Carteron N. L. et al., "Treatment of Murine Lupus with F(ab′)2 Fragments of Monoclonal Antibody to L3T4: suppression of autoimmunity does not depend on T helper cell depletion.," J Immunol., 142:1470-75 (1988).
Choy E.H.S. et al., "Effect of a Humanised Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) on Synovial Fluid (SF) in Rheumatoid Arthritis (RA)," Arthritis & Rheumatism, 40(9)(Supplement):S52, Abstract No. 130 (1997).
Choy E.H.S. et al., "T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment II: Clinical Activity is Related to Pharmacodynamic Effects," Arthritis & Rheumatism, 39(9)(Supplement):S244, Abstract No. 1301 (1996).
Choy E.H.S. et al., "T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment II: Clinical Activity is Related to Pharmacodynamic Effects," Immunology, 89(Supplement 1):92, Abstract No. Ogg379 (1996).
Coleman P. M. Research in Immunology, 145:33-36, 1994. *
Connolly D.J.A. et al., "T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment III: Immunological Effects," Arthritis & Rheumatism, 39(9)(Supplement):S244, Abstract No. 1302 (1996).
Crowe et al., Nucleic Acid Research, 17, 1989, p. 7992.
Crowe J.S. et al., "Nucleotide Sequence of Y3-Ag 1.2.3. Rat Myeloma Immunoglobulin Kappa Chain cDNA," Nucleic Acids Res., 17:7992 (1989).
Cunningham B.C. et al., "Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis," Science, 243:1330-36 (1989).
Daugherty B.L. et al., "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," Nucleic Acids Res., 19:2471-76 (1991).
Daugherty et al., Nucleic Acids Research, 19, 1991, pp. 2471-2476.
Decision revoking the European Patent (Article 102(1)EPC), Appln. No./Patent No. 91 907 669.5-2116/0549581, Nov. 2, 2000.
Dillman et al Ann. Int. Med. 111:592-603 1989. *
Dillman R.O., "Monoclonal Antibodies for Treating Cancer," Ann Intern Med., 111:592-603 (1989).
Epp et al. Biochemistry, 14(22):4943-4952, Nov. 4, 1975. *
Gorman et al. Proc. Natl. Acad. Sci. USA, 88:4181-4185, May 1991. *
Gorman et al., Proc. Natl. Acad. Sci. USA, 88, 1991, pp. 4181-4185.
Gorman S.D. et al., "Humanisation of monoclonal Antibodies for Therapy," Semin in Immunol., 2:457-66 (1990).
Hafler et al. The Journal of Immunology, 141(1):131-138, Jul. 1, 1988. *
Harris et al TibTech 11:42-46 1993. *
Harris W.J. et al., "Therapeutic Antibodies-the coming of age," Trends Biotechnol., 11:42-46 (1993).
Hird et al Genes & Cancer 1990 Wiley & Sons Pub Ch 17. *
Jones et al (Nature 321:522-525 (1986)). *
Jones et al., Nature, 321 (1986), pp. 522-525.
Jones P.T. et al., "Replacing the Complementarity-Determining Regions in a Human ANtibody with Those from a Mouse," Nature, 321:522-25 (1986).
Kettleborough C.A. et al., "Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: the importance of framework residues on loop conformation," Protein Eng., 4:773-83 (1991).
Kettleborough, et al., Protein Engineering, 4:7, 1991, pp. 773-784 (ABST).
Lazar E. et al., "Transforming Growth Factor Alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities," Mol Cell Biol., 8:1247-52 (1988).
Lazar et al., Molecular and Cellular Biology, 8(3); 1247-1252, 1988.
Lewis A.P. et al., "Immunoglobulin Complementarity-Determining Region Grafting by Recombinant Polymerase Chain Reaction to Generate Humanised Monoclonal Antibodies," Gene, 101:297:302 (1991).
Lewis, et al., Gene, 101, pp. 297-302.
Mathieson et al N. Eng. J. Mel 323:250-254 1990. *
Mathieson et al. New England Journal of Medicine, 323:250-254, Jul. 26, 1990. *
Mathieson P.W. et al., Monoclonal-Antibody Therapy in Systemic Vasculitis, N. Engl J Med., 323:250-54 (1990).
Orlandi et al., Proc. Natl. Acad. Sci. USA, 86, 1989, pp. 3833-3847.
Orlandi R. et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," Proc Natl Acad Sci, 86:3833-37 (1989).
Osband et al Imm. Today 11:193-195 1990. *
Osband M.E. et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," Immunol Today, 11:193-95 (1990).
Panayi G.S. et al., "T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment I: Suppression of disease activity and acute phase response," Arthritis & Rheumatism, 39(9)(Supplement):S244, Abstract No. 1300 (1996).
Panayi G.S. et al., "T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment I: Suppression of disease activity and acute phase response," Immunology 89(Supplement 1):92, Abstract No. Ogg379 (1996).
Panka et al. Proc. Natl. Acad. Sci. USA 85:3080-3084, May 1988. *
Presta L.G. et al., "Humanization of an Antibody Directed Against IgE," J Immunol., 151:2623-32 (1993).
Queen C. et al., "A Humanized Antibody that Binds to the Interleukin 2 Receptor," Proc Natl Acad Sci., 86:10029-33 (1989).
Queen et al., Proc. Natl. Acad. Sci. USA, 86, 1989, pp. 10029-10033.
Reichmann, L., et al., Nature, 332, 1988, 323-327.
Riechmann et al. (Nature 332: 323-327 (1988)). *
Riechmann L. et al., "Reshaping Human Antibodies for Therapy," Nature, 332:323-27 (1988).
Roberts et al., Nature, 328, 1987, pp. 731-734.
Roberts S. et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering " Nature 328:731-34 1987.
Rostapshov V.M. et al., "Effective Method for Obtaining Long Nucleotide Chains on Partially Complementary Templates: Processed bovine gamma-interferon gene obtained from human gamma-interferon gene," FEBS Lett., 249:379-82 (1989).
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982. *
Sambrook J. et al., "Oligonucleotide-Mediated Mutagenesis," Molecular Cloning 2nd Ed. 15.51-15.56 (1989).
Sharon J., "Structural Correlates of High Antibody Affinity: Three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold," Proc Natl Acad Sci, 87:4814-17 (1990).
Sharon, Proc. Natl. Acad. Sci. USA, 87, 1990, pp. 4814-4817.
Tao M.H. et al., "Studies of Aglycosylated Chimeric Mouse-Human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region," J Immunol., 143:2595-601 (1989).
Tao, et al., Journal of Immunology, 143(8), 1989, pp. 2595-2601.
U.S. Appl. No. 11/114,233; Non-Final Office Action dated Jan. 4, 2008.
Verhoeyen et al., Science, 239, 1988, pp. 1534-1536.
Verhoeyen M. et al., "Reshaping Human Antibodies: Grafting an antilysozyme activity," Science, 239:1534-36 (1988).
Waldmann 252: 1657-1661 1991. *
Waldmann T.A., "Monoclonal Antibodies in Diagnosis and Therapy," Science, 252:1657-62 (1991).
Waldmann, Science, 252, 1991, pp. 1657-1662.
Ward E.S., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli," Nature, 341:544-46 (1989).
Ward et al., Nature, 341, 1989, pp. 544-546.
Werther W.A. et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1," J Immunol., 157:4986-95 (1996).
William E. Paul. Fundamental Immunology, 3rd Ed., pp. 292-295, 1993. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46877E1 (en) * 1990-09-17 2018-05-29 Btg International Limited Altered antibodies and their preparation

Also Published As

Publication number Publication date
CA2091769A1 (en) 1992-03-18
WO1992005274A1 (en) 1992-04-02
NZ239826A (en) 1992-12-23
JPH06502762A (ja) 1994-03-31
GR3023252T3 (en) 1997-07-30
DE69124387T3 (de) 2011-02-17
IE913257A1 (en) 1992-02-25
IL99499A0 (en) 1992-08-18
IL99499A (en) 2006-08-20
EP0549581B2 (en) 2010-04-28
US20070212753A1 (en) 2007-09-13
MX9101117A (es) 1992-05-04
ZA917407B (en) 1992-06-24
USRE46877E1 (en) 2018-05-29
KR100217212B1 (ko) 1999-10-01
AU660151B2 (en) 1995-06-15
DE69124387D1 (de) 1997-03-06
KR930702535A (ko) 1993-09-09
US6767996B1 (en) 2004-07-27
EP0549581A1 (en) 1993-07-07
CA2091769C (en) 2002-07-23
ID1044B (id) 1996-10-28
US7098006B1 (en) 2006-08-29
DK0549581T3 (da) 1997-05-26
ES2097808T3 (es) 1997-04-16
DE69124387T2 (de) 1997-05-15
EP0549581B1 (en) 1997-01-22
GB9020282D0 (en) 1990-10-31
ATE148172T1 (de) 1997-02-15
AU8508891A (en) 1992-04-15
MY111682A (en) 2000-11-30

Similar Documents

Publication Publication Date Title
USRE43898E1 (en) Altered antibodies and their preparation
JP3081641B2 (ja) 抗体の調製
KR100191152B1 (ko) Cd4 특이적 재조합 항체
US6180377B1 (en) Humanized antibodies
JP3913965B2 (ja) ヒトインターロイキン−６受容体に対するキメラ抗体
AU751064B2 (en) Antibodies against human CD40
EP1694706B1 (en) Modified anti-cd52 antibody
US20020164788A1 (en) Humanized antibodies to CD38
US20050158305A1 (en) Humanized antibodies to CD38
US20080227957A1 (en) Reducing Immunogenicities of Immunoglobulins by Framework-Patching
ZA200100478B (en) Hybrid human/rodent igg antibody to cd3, and methods of its construction.
JPH07504808A (ja) Ｃｄｒをグラフトしたヒト化キメラｔ細胞抗体
KR20080039843A (ko) 만성 림프구성 백혈병의 치료를 위한 ｃｄ52 에 대한모노클로날 항체의 제조를 위한 재조합 방법
ES et al. RAHMENBAU-MUTIERTE ANTIKÖRPER UND IHRE HERSTELLUNG ANTICORPS A MUTATION DE SQUELETTE ET LEUR PREPARATION
JP2022521850A (ja) 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: BTG INTERNATIONAL LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRITISH TECHNOLOGY GROUP INTERCORPORATE LICENSING LIMITED;REEL/FRAME:030372/0013

Effective date: 20130213

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 12

CC Certificate of correction